Rise Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rise Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-439	Closed	-$23.8K	–	278
2025 Q3	$23.8K	Buy	439 +9	+2%	+$515	0.01%	476
2025 Q2	$23.6K	Hold	430	–	–	0.01%	441
2025 Q1	$30.4K	Buy	+430	New	+$28.9K	0.01%	322
2024 Q4	–	Sell	-22	Closed	-$1.55K	–	1129
2024 Q3	$1.55K	Hold	22	–	–	﹤0.01%	1141
2024 Q2	$1.81K	Hold	22	–	–	﹤0.01%	1128
2024 Q1	$1.92K	Hold	22	–	–	﹤0.01%	1143
2023 Q4	$2.12K	Hold	22	–	–	﹤0.01%	461
2023 Q3	$1.95K	Buy	22 +15	+214%	+$1.33K	﹤0.01%	470
2023 Q2	$607	Hold	7	–	–	﹤0.01%	606
2023 Q1	$681	Hold	7	–	–	﹤0.01%	703
2022 Q4	$724	Hold	7	–	–	﹤0.01%	684
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	602
2022 Q2	$1K	Hold	7	–	–	﹤0.01%	611
2022 Q1	$1K	Hold	7	–	–	﹤0.01%	584
2021 Q4	$618	Buy	+7	New	+$578	﹤0.01%	617

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Rise Advisors's BMRN Position: Q4 2025 in Review

Rise Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 439 shares — an estimated $23.8K sold.

Rise Advisors first reported a position in BMRN in Q4 2021 and held it in 15 quarters. The position peaked at $30.4K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Rise Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 439 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $23.8K.
Rise Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 15 quarters.
Rise Advisors's BioMarin Pharmaceuticals position peaked at $30.4K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.